Sangamo Therapeutics Inc. (SGMO)

18.15
0.90 4.70
NASDAQ : Health Technology
Prev Close 19.05
Open 19.05
Day Low/High 17.70 / 19.25
52 Wk Low/High 4.05 / 27.50
Volume 1.96M
Avg Volume 2.25M
Exchange NASDAQ
Shares Outstanding 86.34M
Market Cap 1.66B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotechs Take the Lead This Morning

Biotechs Take the Lead This Morning

Whether this market continues to bounce is going to depend a great degree on the FAANG names.

2 Biotech Stocks to Consider

2 Biotech Stocks to Consider

Many stocks are already at support levels and are offering opportunities to start some positions.

Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program

Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program

Study provided proof of concept for development of SB-913 product candidate currently being evaluated in Phase 1/2 clinical trial

Why Gun-Shy Market Bulls Can't Pull the Trigger Like They Used To

Why Gun-Shy Market Bulls Can't Pull the Trigger Like They Used To

4 stocks on my shopping list for when conditions improve.

Strange: Bullish SGMO Analysts Actually See -8.91% Downside

Strange: Bullish SGMO Analysts Actually See -8.91% Downside

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Sangamo Therapeutics Inc . The average 12-month price target for SGMO — averaging the work of 6 analysts — reveals an average price target of $23.50/share.

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.

Kite, A Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

Kite, A Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

-- Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology --

Biotech Gold Rush Starts to Pick Up; Xerox, Fujifilm Saga Continues -- ICYMI

Biotech Gold Rush Starts to Pick Up; Xerox, Fujifilm Saga Continues -- ICYMI

Here's what you need to know now for Wednesday, Feb. 14.

Biotech Heats Up as Fear of Missing Out Returns

Biotech Heats Up as Fear of Missing Out Returns

It's hard to believe the bounce will continue to run in V-shaped fashion.

Seeing Good Action in Several Stocks, Buying More MJ, Gold

Seeing Good Action in Several Stocks, Buying More MJ, Gold

It is a very different market environment now which can be very rewarding depending on your style.

Focused on Two Sectors

Focused on Two Sectors

If we have a little consolidating action here the buyers will start pushing again.

Indexes Are Holding Up Well, For Now

Indexes Are Holding Up Well, For Now

There are signs of stabilization, but the market is still digesting some very big swings.

Traders Need to Adapt to a New Reality

Traders Need to Adapt to a New Reality

The volatility trade that propped up markets is no longer available.

This Market Badly Needs a Rest

This Market Badly Needs a Rest

It would be a longer-term positive if the overbought conditions are alleviated.

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic

What drives the trading action are structural issues, not macroeconomic news events or political drama.

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

Selling Action Is Upon Us

Selling Action Is Upon Us

There is still a very strong appetite for individual stocks with momentum.

TheStreet Quant Rating: D (Sell)